This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.

A combination of an electrochemical device for delivering reducing equivalents to a cell, and engineered metabolic pathways within the cell capable of utilizing the electrochemically provided reducing equivalents is disclosed. Such a combination allows the production of commodity chemicals by fermentation to proceed with increased carbon efficiency.

Disclosed are transaminase (TA) enzymes and nucleic acids encoding them. In some cases, the transaminase enzymes are non-natural, engineered transaminases. Also disclosed are biosynthetic methods and engineered microorganisms that enhance or improve the biosynthesis of 6-aminocaproate, hexamethylenediamine, caproic acid, caprolactone, or caprolactam. The engineered microorganisms include exogenous TA and in some cases engineered TA.

Provided are genetically engineered microorganism that catalyze the synthesis of propane and/or butanol from a suitable substrate such as glucose. Also provided are methods of engineering said genetically engineered microorganism and methods of producing propane and/or butanol using the genetically engineered microorganism.

Disclosed are biosynthetic methods and engineered microorganism that enhance or improve the biosynthesis of hexamethylenediamine, caproic acid or caprolactam. The engineered microorganisms include selected aldehyde dehydrogenase activity.

This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.

A Saccharomyces cerevisiae strain with high yield of ethyl butyrate and a construction method and an application thereof are provided. The strain is obtained by over-expressing in the starting strain acetyl coenzyme A acyl transferase gene Erg10, 3-hydroxybutyryl coenzyme A dehydrogenase gene Hbd, 3-hydroxybutyryl coenzyme A dehydratase gene Crt, trans-2-enoyl coenzyme A reductase gene Ter, and alcohol acyl transferase gene AAT. Compared to the starting bacteria not producing ethyl butyrate, the yield of ethyl butyrate of the constructed strain reaches 77.33±3.79 mg/L, the yield of the ethyl butyrate of the strain with double copy expression of gene Ter and gene AAT reaches 99.65±7.32 mg/L, increased by 28.9% compared with the EST strain, and 40.93±3.18 mg/L of ethyl crotonate is unexpectedly produced.

Disclosed are trans-enoyl CoA reductase (TER) enzymes and nucleic acids encoding them. In some cases, the TER enzymes are non-natural, engineered trans-enoyl CoA reductase. TER enzymes were shown to catalyse the conversion of 5-carboxy-2-pentenoyl-CoA into adipyl-CoA for improved adipate production and the conversion of crotonyl-CoA into 6-aminocaproate. The enzymes can be used in biosynthetic methods and engineered microorganisms that enhance or improve the biosynthesis of 6-aminocaproate, hexamethylenediamine, caproic acid, caprolactone, or caprolactam. The engineered microorganisms include exogenous TER and in some cases engineered TER.

A Saccharomyces cerevisiae strain with high yield of ethyl butyrate and a construction method and an application thereof are provided. The strain is obtained by over-expressing in the starting strain acetyl coenzyme A acyl transferase gene Erg10, 3-hydroxybutyryl coenzyme A dehydrogenase gene Hbd, 3-hydroxybutyryl coenzyme A dehydratase gene Crt, trans-2-enoyl coenzyme A reductase gene Ter, and alcohol acyl transferase gene AAT. Compared to the starting bacteria not producing ethyl butyrate, the yield of ethyl butyrate of the constructed strain reaches 77.33±3.79 mg/L, the yield of the ethyl butyrate of the strain with double copy expression of gene Ter and gene AAT reaches 99.65±7.32 mg/L, increased by 28.9% compared with the EST strain, and 40.93±3.18 mg/L of ethyl crotonate is unexpectedly produced.

The disclosure relates to the field of specialty chemicals and methods for their synthesis. In embodiments, the disclosure provides viable bacterial cells which comprise heterologous dual 3-hydroxy-acyl-ACP dehydratase/isomerases, etc. The disclosure further provides monounsaturated fatty acid derivative molecules produced by the viable bacterial cells which are non-native to the bacterial cells. The disclosure further provides methods for the preparation and production of non-native monounsaturated fatty acid derivative molecules such as e.g., an ω3-monounsaturated fatty acid derivative, an ω5-monounsaturated fatty acid derivative, an ω9-monounsaturated fatty acid derivative, an ω11-monounsaturated fatty acid fatty acid derivative, etc.